Cargando…

Postinfectious Hemolytic Uremic Syndrome

Post-infectious hemolytic uremic syndrome (HUS) is caused by specific pathogens in patients with no identifiable HUS-associated genetic mutation or autoantibody. The majority of episodes is due to infections by Shiga toxin (Stx) producing Escherichia coli (STEC). This chapter reviews the epidemiolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitzan, Martin, Lapeyraque, Anne-Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121170/
http://dx.doi.org/10.1007/978-3-662-52972-0_26
_version_ 1783515142600785920
author Bitzan, Martin
Lapeyraque, Anne-Laure
author_facet Bitzan, Martin
Lapeyraque, Anne-Laure
author_sort Bitzan, Martin
collection PubMed
description Post-infectious hemolytic uremic syndrome (HUS) is caused by specific pathogens in patients with no identifiable HUS-associated genetic mutation or autoantibody. The majority of episodes is due to infections by Shiga toxin (Stx) producing Escherichia coli (STEC). This chapter reviews the epidemiology and pathogenesis of STEC-HUS, including bacterial-derived factors and host responses. STEC disease is characterized by hematological (microangiopathic hemolytic anemia), renal (acute kidney injury) and extrarenal organ involvement. Clinicians should always strive for an etiological diagnosis through the microbiological or molecular identification of Stx-producing bacteria and Stx or, if negative, serological assays. Treatment of STEC-HUS is supportive; more investigations are needed to evaluate the efficacy of putative preventive and therapeutic measures, such as non-phage-inducing antibiotics, volume expansion and anti-complement agents. The outcome of STEC-HUS is generally favorable, but chronic kidney disease, permanent extrarenal, mainly cerebral complication and death (in less than 5 %) occur and long-term follow-up is recommended. The remainder of this chapter highlights rarer forms of (post-infectious) HUS due to S. dysenteriae, S. pneumoniae, influenza A and HIV and discusses potential interactions between these pathogens and the complement system.
format Online
Article
Text
id pubmed-7121170
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-71211702020-04-06 Postinfectious Hemolytic Uremic Syndrome Bitzan, Martin Lapeyraque, Anne-Laure Pediatric Kidney Disease Article Post-infectious hemolytic uremic syndrome (HUS) is caused by specific pathogens in patients with no identifiable HUS-associated genetic mutation or autoantibody. The majority of episodes is due to infections by Shiga toxin (Stx) producing Escherichia coli (STEC). This chapter reviews the epidemiology and pathogenesis of STEC-HUS, including bacterial-derived factors and host responses. STEC disease is characterized by hematological (microangiopathic hemolytic anemia), renal (acute kidney injury) and extrarenal organ involvement. Clinicians should always strive for an etiological diagnosis through the microbiological or molecular identification of Stx-producing bacteria and Stx or, if negative, serological assays. Treatment of STEC-HUS is supportive; more investigations are needed to evaluate the efficacy of putative preventive and therapeutic measures, such as non-phage-inducing antibiotics, volume expansion and anti-complement agents. The outcome of STEC-HUS is generally favorable, but chronic kidney disease, permanent extrarenal, mainly cerebral complication and death (in less than 5 %) occur and long-term follow-up is recommended. The remainder of this chapter highlights rarer forms of (post-infectious) HUS due to S. dysenteriae, S. pneumoniae, influenza A and HIV and discusses potential interactions between these pathogens and the complement system. 2016-06-17 /pmc/articles/PMC7121170/ http://dx.doi.org/10.1007/978-3-662-52972-0_26 Text en © Springer-Verlag Berlin Heidelberg 2016 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Bitzan, Martin
Lapeyraque, Anne-Laure
Postinfectious Hemolytic Uremic Syndrome
title Postinfectious Hemolytic Uremic Syndrome
title_full Postinfectious Hemolytic Uremic Syndrome
title_fullStr Postinfectious Hemolytic Uremic Syndrome
title_full_unstemmed Postinfectious Hemolytic Uremic Syndrome
title_short Postinfectious Hemolytic Uremic Syndrome
title_sort postinfectious hemolytic uremic syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121170/
http://dx.doi.org/10.1007/978-3-662-52972-0_26
work_keys_str_mv AT bitzanmartin postinfectioushemolyticuremicsyndrome
AT lapeyraqueannelaure postinfectioushemolyticuremicsyndrome